150 related articles for article (PubMed ID: 36923305)
21. Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Shoushtari AN; Olszanski AJ; Nyakas M; Hornyak TJ; Wolchok JD; Levitsky V; Kuryk L; Hansen TB; Jäderberg M
Clin Cancer Res; 2023 Jan; 29(1):100-109. PubMed ID: 36112545
[TBL] [Abstract][Full Text] [Related]
22. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
[TBL] [Abstract][Full Text] [Related]
23. Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.
Karapetyan L; AbuShukair HM; Li A; Knight A; Al Bzour AN; MacFawn IP; Thompson ZJ; Chen A; Yang X; Dadey R; Karunamurthy A; De Stefano DV; Sander C; Kunning SR; Najjar YG; Davar D; Luke JJ; Gooding W; Bruno TC; Kirkwood JM; Storkus WJ
Front Immunol; 2023; 14():1171978. PubMed ID: 37435077
[TBL] [Abstract][Full Text] [Related]
24. A novel prognostic signature of chemokines for survival and immune infiltration in kidney renal clear cell carcinoma.
Weng J; Huang Z; Li Q; Huang Y; Chen S
Int J Med Sci; 2023; 20(8):1046-1059. PubMed ID: 37484803
[No Abstract] [Full Text] [Related]
25. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
26. Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy.
Hoch T; Schulz D; Eling N; Gómez JM; Levesque MP; Bodenmiller B
Sci Immunol; 2022 Apr; 7(70):eabk1692. PubMed ID: 35363540
[TBL] [Abstract][Full Text] [Related]
27. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
29. TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
Mauldin IS; Wang E; Deacon DH; Olson WC; Bao Y; Slingluff CL
Int J Cancer; 2015 Sep; 137(6):1386-96. PubMed ID: 25765738
[TBL] [Abstract][Full Text] [Related]
30. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
31. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.
Kocher F; Puccini A; Untergasser G; Martowicz A; Zimmer K; Pircher A; Baca Y; Xiu J; Haybaeck J; Tymoszuk P; Goldberg RM; Petrillo A; Shields AF; Salem ME; Marshall JL; Hall M; Korn WM; Nabhan C; Battaglin F; Lenz HJ; Lou E; Choo SP; Toh CK; Gasteiger S; Pichler R; Wolf D; Seeber A
Clin Cancer Res; 2022 Nov; 28(22):4957-4967. PubMed ID: 36112544
[TBL] [Abstract][Full Text] [Related]
32. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
Arance A; de la Cruz-Merino L; Petrella TM; Jamal R; Ny L; Carneiro A; Berrocal A; Márquez-Rodas I; Spreafico A; Atkinson V; Costa Svedman F; Mant A; Khattak MA; Mihalcioiu C; Jang S; Cowey CL; Smith AD; Hawk N; Chen K; Diede SJ; Krepler C; Long GV
J Clin Oncol; 2023 Jan; 41(1):75-85. PubMed ID: 35867951
[TBL] [Abstract][Full Text] [Related]
33. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
34. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
35. Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.
Frias A; Di Leo L; Antoranz A; Nazerai L; Carretta M; Bodemeyer V; Pagliuca C; Dahl C; Claps G; Mandelli GE; Andhari MD; Pacheco MP; Sauter T; Robert C; Guldberg P; Madsen DH; Cecconi F; Bosisio FM; De Zio D
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36868570
[TBL] [Abstract][Full Text] [Related]
36. VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma.
Wu X; Giobbie-Hurder A; Liao X; Lawrence D; McDermott D; Zhou J; Rodig S; Hodi FS
Cancer Immunol Res; 2016 Oct; 4(10):858-868. PubMed ID: 27549123
[TBL] [Abstract][Full Text] [Related]
37. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
38. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
39. CSF-1R inhibitor, pexidartinib, sensitizes esophageal adenocarcinoma to PD-1 immune checkpoint blockade in a rat model.
Omstead AN; Paskewicz M; Gorbunova A; Zheng P; Salvitti MS; Mansoor R; Reed P; Ballengee S; Wagner PL; Jobe BA; Kelly RJ; Zaidi AH
Carcinogenesis; 2022 Oct; 43(9):842-850. PubMed ID: 35552655
[TBL] [Abstract][Full Text] [Related]
40. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
